Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Follow-Up Questions
Who is the CEO of Entera Bio Ltd?
Ms. Miranda Toledano is the Chief Executive Officer of Entera Bio Ltd, joining the firm since 2018.
What is the price performance of ENTX stock?
The current price of ENTX is $1.79, it has decreased 0.55% in the last trading day.
What are the primary business themes or industries for Entera Bio Ltd?
Entera Bio Ltd belongs to Biotechnology industry and the sector is Health Care
What is Entera Bio Ltd market cap?
Entera Bio Ltd's current market cap is $81.7M
Is Entera Bio Ltd a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Entera Bio Ltd, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
